Skip to main content

Infectious Diseases Fellows will have the opportunity to work with internal and external partners during their training.

UNC Center for AIDS Research (CFAR)

The UNC CFAR is a consortium of three complementary institutions – UNC, RTI International and FHI 360. The purpose of the UNC CFAR is to provide infrastructure to support investigation of the HIV/AIDS epidemic using clinical research, behavioral research, research into HIV biology and pathogenesis at the molecular level, and educational outreach. The CFAR does this by working closely with the UNC Institute of Global Health & Infectious Diseases, the UNC HIV Cure Center, and the UNC Global HIV Prevention and Treatment Clinical Trials Unit.

The UNC CFAR provides incentive for cross-fertilization within one of the largest groups of scientists in the country, one that covers the entire spectrum of HIV/AIDS-related research. The current UNC CFAR membership includes over 200 active researchers and over three times that many researchers receive news of CFAR events, programs and HIV/AIDS-related funding opportunities. In addition, the CFAR provides developmental awards to young investigators and those new to HIV/AIDS research at our three partnering institutions, and to investigators at NC State and at historically black colleges and universities across the state.

AIDS Clinical Trials Group Network (ACTG)

The AIDS Clinical Trials Group (ACTG) was initially established in 1987 to broaden the scope of the AIDS research effort of the National Institute of Allergy and Infectious Diseases (NIAID). The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities.

The work accomplished by the ACTG has had a profound impact on the well-being of persons infected with HIV-1. Clinical trials and laboratory studies conducted by the ACTG have made major contributions to optimizing antiretroviral therapy (ART), managing drug resistance, preventing and treating co-infections, evaluating acute and long-term toxicities, and demonstrating the importance of pharmacogenomics in predicting drug toxicities. Results of these studies have helped establish the paradigm for the management of HIV disease and form the basis of current treatment guidelines. This progress in the treatment of HIV-1-infected individuals has resulted in dramatic reductions in AIDS mortality in the U.S. and other countries of the developed world.

The mission of the ACTG is to cure HIV infection and reduce the burden of disease due to HIV infection and its complications, including tuberculosis and viral hepatitis.

HIV Prevention Trials Network (HPTN)

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection. The HPTN research agenda is focused primarily on the use of integrated strategies: use of antiretroviral drugs (antiretroviral therapy and pre-exposure prophylaxis); interventions for substance abuse, particularly injection drug use; behavioral risk reduction interventions and structural interventions. NIH funds HPTN. For more information, visit

North Carolina AIDS Training and Education Center (NCATEC)

The mission of the N.C. AIDS Training and Education Center is to meet the training needs of health care professionals who work to prevent and treat HIV. The scope of the NCATEC’s mission includes STIs and hepatitis C, and trainings are developed to meet the needs of clinicians, case managers, social workers, substance abuse counselors, and all who work in HIV care.